565 related articles for article (PubMed ID: 20601954)
1. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Nikoloski G; Langemeijer SM; Kuiper RP; Knops R; Massop M; Tönnissen ER; van der Heijden A; Scheele TN; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2010 Aug; 42(8):665-7. PubMed ID: 20601954
[TBL] [Abstract][Full Text] [Related]
2. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
Ernst T; Chase AJ; Score J; Hidalgo-Curtis CE; Bryant C; Jones AV; Waghorn K; Zoi K; Ross FM; Reiter A; Hochhaus A; Drexler HG; Duncombe A; Cervantes F; Oscier D; Boultwood J; Grand FH; Cross NC
Nat Genet; 2010 Aug; 42(8):722-6. PubMed ID: 20601953
[TBL] [Abstract][Full Text] [Related]
3. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
Wang JY; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of EZH2 expression in myelodysplastic syndromes.
Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
7. The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
Xu F; Li X
Expert Rev Hematol; 2012 Apr; 5(2):177-85. PubMed ID: 22475286
[TBL] [Abstract][Full Text] [Related]
8. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
[TBL] [Abstract][Full Text] [Related]
9. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Bate-Eya LT; Gierman HJ; Ebus ME; Koster J; Caron HN; Versteeg R; Dolman MEM; Molenaar JJ
Eur J Cancer; 2017 Apr; 75():63-72. PubMed ID: 28214660
[TBL] [Abstract][Full Text] [Related]
11. Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.
Puda A; Milosevic JD; Berg T; Klampfl T; Harutyunyan AS; Gisslinger B; Rumi E; Pietra D; Malcovati L; Elena C; Doubek M; Steurer M; Tosic N; Pavlovic S; Guglielmelli P; Pieri L; Vannucchi AM; Gisslinger H; Cazzola M; Kralovics R
Am J Hematol; 2012 Mar; 87(3):245-50. PubMed ID: 22190018
[TBL] [Abstract][Full Text] [Related]
12. The NSD1 and EZH2 overgrowth genes, similarities and differences.
Tatton-Brown K; Rahman N
Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):86-91. PubMed ID: 23592277
[TBL] [Abstract][Full Text] [Related]
13. Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.
Katoh M
Epigenomics; 2016 Feb; 8(2):285-305. PubMed ID: 26411517
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
15. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract][Full Text] [Related]
16. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
[TBL] [Abstract][Full Text] [Related]
17. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
Wang J; Ai X; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Hu N; Zhang Y; Xiao Z
Leuk Res; 2013 Mar; 37(3):305-11. PubMed ID: 23099237
[TBL] [Abstract][Full Text] [Related]
18. Aberrant Expression of
de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
[TBL] [Abstract][Full Text] [Related]
19. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
[TBL] [Abstract][Full Text] [Related]
20. Roles of the EZH2 histone methyltransferase in cancer epigenetics.
Simon JA; Lange CA
Mutat Res; 2008 Dec; 647(1-2):21-9. PubMed ID: 18723033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
